Table 1.

Clinical and Epidemiologic Features of Nine Patients With ALPS

Patient No.Age at PresentationRace/SexPresenting FeaturesAdenopathy*Splenomegaly/HepatomegalyNeutropeniaAutoimmune Disease
4 mo W/M Adenopathy 3+ +/+ − ITP 
   Hepatosplenomegaly     
18 mo W/F Adenopathy 4+ +/+ − Glomerulonephritis, positive ANA 
   Hepatosplenomegaly    Hemolytic anemia 
5 yr W/M Adenopathy 2+ +/− Hemolytic anemia, ITP 
   Splenomegaly     
2 yr W/M Adenopathy 3+ +/+ Urticarial rash 
   Hepatosplenomegaly     
2 mo W/M Splenomegaly 4+ +/− Hemolytic anemia, ITP 
4 mo B/F Adenopathy 4+ +/+ − Hemolytic anemia 
   Splenomegaly     
14 9 mo W/F Splenomegaly 4+ +/+ − Hemolytic anemia 
   Hemolytic anemia     
17 4 mo W/F Adenopathy 4+ +/+ Hemolytic anemia 
   Hepatosplenomegaly     
20 3 yr W/F Adenopathy 2+ +/+ − Guillain-Barrè syndrome 
   Hepatosplenomegaly     
Patient No.Age at PresentationRace/SexPresenting FeaturesAdenopathy*Splenomegaly/HepatomegalyNeutropeniaAutoimmune Disease
4 mo W/M Adenopathy 3+ +/+ − ITP 
   Hepatosplenomegaly     
18 mo W/F Adenopathy 4+ +/+ − Glomerulonephritis, positive ANA 
   Hepatosplenomegaly    Hemolytic anemia 
5 yr W/M Adenopathy 2+ +/− Hemolytic anemia, ITP 
   Splenomegaly     
2 yr W/M Adenopathy 3+ +/+ Urticarial rash 
   Hepatosplenomegaly     
2 mo W/M Splenomegaly 4+ +/− Hemolytic anemia, ITP 
4 mo B/F Adenopathy 4+ +/+ − Hemolytic anemia 
   Splenomegaly     
14 9 mo W/F Splenomegaly 4+ +/+ − Hemolytic anemia 
   Hemolytic anemia     
17 4 mo W/F Adenopathy 4+ +/+ Hemolytic anemia 
   Hepatosplenomegaly     
20 3 yr W/F Adenopathy 2+ +/+ − Guillain-Barrè syndrome 
   Hepatosplenomegaly     

Abbreviations: W, white; B, black; ITP, idiopathic thrombocytopenic purpura.

*

Multiple chains of 1- to 2-cm nodes indicated by 2+, multiple chains of nodes visible without palpation by 3+, and massive adenopathy distorting normal anatomical landmarks by 4+.

Positive immunofluorescent assay for antinuclear antibody, 1:320 nucleolar pattern.

Direct antiglobulin (Coomb's) test was positive for both IgG and C3d in all patients with hemolytic anemia.

Close Modal

or Create an Account

Close Modal
Close Modal